Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.
Condition or disease
Drug: VancomycinDrug: Vancomycin plus GentamicinDrug: Vancomycin plus RifampinDrug: Vancomycin plus Gentamicin plus Rifampin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 64 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with MRSA in a blood culture processed as standard of care at the VAMC
Patients or next of kin willing to sign consent to be randomized by social security number to one of the treatments.